INmune Bio gains as trial for prostate cancer therapy succeeds
INmune Bio's Trial Success: INmune Bio's shares rose approximately 18% after the company announced that its Phase 1/2 trial for the cell therapy INKmune met its primary and secondary endpoints in patients with metastatic castration-resistant prostate cancer (mCRPC).
Future Plans for INKmune: Following the successful trial results, INmune Bio plans to initiate a randomized Phase 2b trial for INKmune in patients with less severe forms of prostate cancer.
Trade with 70% Backtested Accuracy
Analyst Views on INMB
About INMB
About the author
INmune Bio Publishes Overview on Future Applications of MSC Therapies
- MSC Therapy Outlook: INmune Bio recently published an overview in the journal Cytotherapy regarding mesenchymal stromal cell (MSC) therapies, highlighting their potential applications in inflammation, immunomodulation, and wound healing, showcasing the company's forward-looking research capabilities in cell therapy.
- CORDStrom™ Platform Progress: The review, led by INmune's Chief Scientist Dr. Nikita M. Patel, discusses systemic and local delivery methods for the CORDStrom™ platform, with plans to file a Biologics License Application (BLA) and Marketing Authorization Application (MAA) in 2026, laying the groundwork for future clinical applications.
- Strengthening Scientific Foundation: The article summarizes the current knowledge base and critical gaps in MSC therapies, aiming to propose experimental questions to enhance the development of the CORDStrom™ platform, indicating INmune's leadership in advancing MSC research.
- Clinical Research Potential: INmune Bio's CORDStrom™ platform utilizes human umbilical cord-derived mesenchymal stromal cells to provide high-quality, reproducible cellular medicines, which may have a significant impact on treating complex inflammatory and autoimmune diseases.
INmune Bio Presents New XPro1595 Data for Alzheimer's Disease at CTAD
- Clinical Trial Progress: INmune Bio presented new neuroimaging data for XPro1595 at the CTAD conference, indicating the drug may slow neurodegenerative progression in early Alzheimer's patients, highlighting its potential in treating inflammation-driven Alzheimer's disease.
- Biomarker Validation: Utilizing PerpPD+ imaging analysis, the study observed a trend towards reduced cortical disarray in patients with high inflammatory burden receiving XPro1595, further validating its mechanism of selectively neutralizing soluble TNF (sTNF).
- Market Opportunity: The findings underscore the unmet medical need for inflammation-driven Alzheimer's disease, positioning XPro1595 as a first-in-class disease-modifying therapy that could present significant commercial opportunities for the company.
- Future Data Outlook: INmune Bio confirmed that additional MRI analyses will be released in 2026, expected to provide further insights into XPro1595's impact on brain tissue in Alzheimer's patients, enhancing its competitive position in the market.
INmune Bio Successfully Completes Initial Commercial Pilot-Scale Production of CORDStrom™ at CGT Catapult
Successful Manufacturing Milestone: INmune Bio Inc. has completed its first full-scale pilot commercial manufacturing run of CORDStrom™, a mesenchymal stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB), at the Cell and Gene Therapy Catapult in the UK, paving the way for regulatory submissions in 2026.
Promising Clinical Results: CORDStrom™ has shown positive outcomes in a Phase 2 trial, improving symptoms such as itch, pain, and wound healing in RDEB patients, highlighting its potential as a life-changing therapy for those affected by this severe condition.
INmune Bio (INMB) Declines 23.8% Over the Past Month, But a Trend Reversal Could Be Imminent
Stock Performance and Technical Analysis: INmune Bio, Inc. (INMB) has experienced a 23.8% decline over the past month, but its current RSI of 27.46 indicates it is oversold, suggesting a potential trend reversal may be imminent.
Analyst Sentiment and Earnings Estimates: There is strong consensus among analysts for improved earnings, with a 15.7% increase in the consensus EPS estimate over the last month, and INMB holds a Zacks Rank #2 (Buy), indicating a favorable outlook for the stock's recovery.
INmune Bio outlines CORDStrom BLA and MAA filings targeted for mid-2026 as CEO transition highlights strategic shift
Management Changes and Strategic Focus: David J. Moss has been appointed as the new CEO of INmune Bio, emphasizing a strategic shift away from developing XPro for Alzheimer's disease due to high costs, while focusing on advancing CORDStrom and INKmune towards regulatory approvals by mid-2026.
Financial Performance and Future Outlook: The company reported a net loss of approximately $24.5 million for Q2 2025, with cash reserves sufficient to fund operations into Q3 2026; management is pursuing partnerships and regulatory submissions to support its pipeline amidst a cautious financial strategy.
INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
Trial Results: INmune Bio's Phase I/II trial of INKmune™ for metastatic castration-resistant prostate cancer has successfully met its primary and secondary endpoints, demonstrating safety and effectiveness in activating NK cells, particularly in patients with low NK cell activation.
Future Plans: Following the trial's success, INmune Bio intends to design a randomized Phase 2b trial targeting patients with less severe disease to further assess the drug's clinical benefits.
INmune Bio Publishes Overview on Future Applications of MSC Therapies
- MSC Therapy Outlook: INmune Bio recently published an overview in the journal Cytotherapy regarding mesenchymal stromal cell (MSC) therapies, highlighting their potential applications in inflammation, immunomodulation, and wound healing, showcasing the company's forward-looking research capabilities in cell therapy.
- CORDStrom™ Platform Progress: The review, led by INmune's Chief Scientist Dr. Nikita M. Patel, discusses systemic and local delivery methods for the CORDStrom™ platform, with plans to file a Biologics License Application (BLA) and Marketing Authorization Application (MAA) in 2026, laying the groundwork for future clinical applications.
- Strengthening Scientific Foundation: The article summarizes the current knowledge base and critical gaps in MSC therapies, aiming to propose experimental questions to enhance the development of the CORDStrom™ platform, indicating INmune's leadership in advancing MSC research.
- Clinical Research Potential: INmune Bio's CORDStrom™ platform utilizes human umbilical cord-derived mesenchymal stromal cells to provide high-quality, reproducible cellular medicines, which may have a significant impact on treating complex inflammatory and autoimmune diseases.
INmune Bio Presents New XPro1595 Data for Alzheimer's Disease at CTAD
- Clinical Trial Progress: INmune Bio presented new neuroimaging data for XPro1595 at the CTAD conference, indicating the drug may slow neurodegenerative progression in early Alzheimer's patients, highlighting its potential in treating inflammation-driven Alzheimer's disease.
- Biomarker Validation: Utilizing PerpPD+ imaging analysis, the study observed a trend towards reduced cortical disarray in patients with high inflammatory burden receiving XPro1595, further validating its mechanism of selectively neutralizing soluble TNF (sTNF).
- Market Opportunity: The findings underscore the unmet medical need for inflammation-driven Alzheimer's disease, positioning XPro1595 as a first-in-class disease-modifying therapy that could present significant commercial opportunities for the company.
- Future Data Outlook: INmune Bio confirmed that additional MRI analyses will be released in 2026, expected to provide further insights into XPro1595's impact on brain tissue in Alzheimer's patients, enhancing its competitive position in the market.
INmune Bio Successfully Completes Initial Commercial Pilot-Scale Production of CORDStrom™ at CGT Catapult
Successful Manufacturing Milestone: INmune Bio Inc. has completed its first full-scale pilot commercial manufacturing run of CORDStrom™, a mesenchymal stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB), at the Cell and Gene Therapy Catapult in the UK, paving the way for regulatory submissions in 2026.
Promising Clinical Results: CORDStrom™ has shown positive outcomes in a Phase 2 trial, improving symptoms such as itch, pain, and wound healing in RDEB patients, highlighting its potential as a life-changing therapy for those affected by this severe condition.
INmune Bio (INMB) Declines 23.8% Over the Past Month, But a Trend Reversal Could Be Imminent
Stock Performance and Technical Analysis: INmune Bio, Inc. (INMB) has experienced a 23.8% decline over the past month, but its current RSI of 27.46 indicates it is oversold, suggesting a potential trend reversal may be imminent.
Analyst Sentiment and Earnings Estimates: There is strong consensus among analysts for improved earnings, with a 15.7% increase in the consensus EPS estimate over the last month, and INMB holds a Zacks Rank #2 (Buy), indicating a favorable outlook for the stock's recovery.
INmune Bio outlines CORDStrom BLA and MAA filings targeted for mid-2026 as CEO transition highlights strategic shift
Management Changes and Strategic Focus: David J. Moss has been appointed as the new CEO of INmune Bio, emphasizing a strategic shift away from developing XPro for Alzheimer's disease due to high costs, while focusing on advancing CORDStrom and INKmune towards regulatory approvals by mid-2026.
Financial Performance and Future Outlook: The company reported a net loss of approximately $24.5 million for Q2 2025, with cash reserves sufficient to fund operations into Q3 2026; management is pursuing partnerships and regulatory submissions to support its pipeline amidst a cautious financial strategy.
INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
Trial Results: INmune Bio's Phase I/II trial of INKmune™ for metastatic castration-resistant prostate cancer has successfully met its primary and secondary endpoints, demonstrating safety and effectiveness in activating NK cells, particularly in patients with low NK cell activation.
Future Plans: Following the trial's success, INmune Bio intends to design a randomized Phase 2b trial targeting patients with less severe disease to further assess the drug's clinical benefits.
